You are here: Industry Insights > Ipsen

News List

Ipsen and Exicure to develop therapies for neurodegenerative disorders pharmaceutical-technology
August 04, 2021
Ipsen and Exicure have entered an exclusive partnership agreement for the research, development and marketing of new spherical nucleic acids (SNAs) for the potential treatment of Huntington’s disease and Angelman syndrome.
Ipsen to collaborate with BAKX Therapeutics on early-stage oncology asset pharmatimes
July 30, 2021
French pharma company Ipsen has entered into a new collaboration agreement with BAKX Therapeutics focused on an oral small-molecule activator of BAX for the potential treatment of leukaemia, lymphoma and solid tumours.
Ipsen and IRLAB sign $363m deal for Parkinson’s disease therapy pharmaceutical-technology
July 19, 2021
Ipsen has entered a licensing agreement with IRLAB to obtain exclusive global development and commercial rights for the latter’s investigational therapy, mesdopetam (IRL790).
FDA Accepts NDA for First Potential Treatment for Fibrodysplasia Ossificans Progressiva americanpharmaceuticalreview
June 04, 2021
Ipsen announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the ...
Opdivo plus Cabometyx approved in the EU for advanced renal cancer pharmatimes
April 01, 2021
The European Commission (EC) has authorised Bristol Myers Squibb’s (BMS) Opdivo plus Ipsen’s Cabometyx as a first-line treatment for advanced renal cell carcinoma (aRCC).
Fusion Pharmaceuticals Acquires IPN-1087 contractpharma
March 03, 2021
Fusion Pharmaceuticals Inc. has entered into an asset purchase agreement (APA) to acquire Ipsen's intellectual property and assets related to IPN-1087.
MHRA grants licence update for Ipsen’s Dysport pharmaceutical-technology
January 09, 2020
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Ipsen’s Dysport.
Ferring spinout FerGene nabs Ipsen's David Meek as CEO firstwordpharma
December 18, 2019
Ipsen announced Wednesday that CEO David Meek has resigned from his position and will assume the chief executive role at FerGene, a new gene therapy company recently launched by Ferring Pharmaceuticals and Blackstone Life Sciences, effective January 14 ne
Ipsen closes $1bn Clementia Pharmaceuticals acquisition pharmaceutical-technology
April 24, 2019
Ipsen has completed an acquisition of Canada-based Clementia Pharmaceuticals to expand its rare diseases portfolio.
Ipsen to buy rare disease firm Clementia for up to $1.31bn pharmaphorum
February 26, 2019
France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.

Previous page 1 2 3 Next page